Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Phase 3 study to evaluate IOP lowering therapy in open angle glaucoma and ocular hypertension C-01-70 Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Phase 3 study to evaluate IOP lowering therapy in open angle glaucoma and ocular hypertension C-01-70 conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase 3 study to evaluate IOP lowering therapy in open angle glaucoma and ocular hypertension C-01-70 Clinical research trials and Phase 3 study to evaluate IOP lowering therapy in open angle glaucoma and ocular hypertension C-01-70 healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Phase 3 study to evaluate IOP lowering therapy in open angle glaucoma and ocular hypertension C-01-70. Phase 3 study to evaluate IOP lowering therapy in open angle glaucoma and ocular hypertension C-01-70 Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Phase 3 study to evaluate IOP lowering therapy in open angle glaucoma and ocular hypertension C-01-70 clinical trial. Subjects frequently obtain the most expert healthcare possible for their Phase 3 study to evaluate IOP lowering therapy in open angle glaucoma and ocular hypertension C-01-70 condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.

Home > "P" Clinical Trials Conditions > Phase 3 study to evaluate IOP lowering therapy in open angle glaucoma and ocular hypertension C-01-70

Phase 3 study to evaluate IOP lowering therapy in open angle glaucoma and ocular hypertension C-01-70



Phase 3 study to evaluate IOP lowering therapy in open angle glaucoma and ocular hypertension C-01-70

For Condition: Ocular Hypertension,Open-Angle Glaucoma
Status: Recruiting
Sponsor(s): Alcon Research ,
Synopsis: To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.
Details:
Eligibility:
Study Type:
  Interventional, Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension; visual acuity of 20/80 to 20/400 or better (Snellen equivalent) or logMAR visual acuity not worse than 0.6. Clinically relevant ophthalmic or systemic conditions may be excluded.
Total Enrollment: 

Location and Contact Information:

Clinical Trial Sites *Recruiting*
Multiple Locations Throughout the United States,  , 

Recruiting  


Additional Information:
Study ID Numbers:
  C-01-70;  C-01-70
Study Start Date: 
Record last reviewed: October 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00047541

Other Ocular Hypertension Studies:
1. A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients with Open-Angle Glaucoma or Ocular Hypertension

2. Mechanism of Action of TRAVATAN 0.004% in Subjects with Glaucoma or Ocular Hypertension

3. A safety and efficacy study of Travoprost 0.004% compared to Latanoprost 0.005% in patients with open-angle glaucoma(OAG) or ocular hypertension(OHT)

4. Pigment Dispersion Syndrome With and Without Glaucoma

5. A 6-week safety & efficacy study of combination intraocular pressure-lowering therapy in patients with open-angle glaucoma or ocular hypertension

Related Studies:

Other Ocular Hypertension Clinical Trials
Other Clinical Trials
Other Multiple Locations Throughout the United States Clinical Trials

Phase 3 study to evaluate IOP lowering therapy in open angle glaucoma and ocular hypertension C-01-70

Modify your Search

  Other Ocular Hypertension Clinical Trials
  Other Clinical Trials
  Other Multiple Locations Throughout the United States Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103